

Autism Spectrum Disorder

**Open Label, Adaptive, Parallel Group PET Study Using RO7017773  
And [11C] RO15-4513**

**Trial Status**  
**Completed**

**Trial Runs In**  
**1 Countries**

**Trial Identifier**  
**NCT03507569 BP40257**

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a single dose (SD), non-randomized, open-label, adaptive, parallel group study with the purpose of investigating the occupancy of alpha5-containing GABAA receptors by RO7017773 in healthy participants.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT03507569 BP40257**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
**All**

**Age**  
**>= 23 Years & <= 55 Years**

**Healthy Volunteers**  
**Accepts Healthy Volunteers**

---